article · Journal of Innovations in Medical Research
Lincomycin is a lincosamide antibiotic that can cause kidney damage by triggering oxidative stress. This study evaluated whether activated charcoal, an established adsorbent, could protect against this toxicity in an animal model. Researchers divided twenty-five Wistar rats into five groups receiving either normal saline, lincomycin alone, or lincomycin alongside activated charcoal at concentrations of 25 percent, 50 percent, or 75 percent. Assessments covered renal function markers including creatinine and urea, oxidative stress indicators such as superoxide dismutase and malondialdehyde, and histopathological changes. Exposure to lincomycin significantly altered kidney function markers and elevated oxidative stress. Co-administering activated charcoal counteracted these detrimental changes, improving both kidney performance indices and antioxidant levels. The outcomes demonstrate that activated charcoal helps preserve renal function and limit oxidative damage during lincomycin treatment.
Antibiotics are essential for treating infections, but drugs like lincomycin can cause serious side effects, including acute kidney damage driven by oxidative stress. Showing that a widely available material like activated charcoal can counteract these harmful effects provides a foundation for developing low-cost supportive measures to safeguard patient kidney health during intensive antibiotic regimens.
This research suggests a potential application for activated charcoal as an adjunct therapeutic to reduce antibiotic-induced kidney toxicity, which could be relevant to pharmaceutical developers and clinical care providers. However, the evidence is limited to an early-stage study in twenty-five rats. Substantial preclinical validation, safety profiling, formulation design, and clinical trials would be required before this approach could be translated into a commercial treatment protocol.
AI-generated from the published abstract. Always read the original work before citing.
Background: The kidneys play a vital role in homeostasis and metabolic waste elimination, but they are highly susceptible to toxic insults due to their role in drug metabolism. Lincomycin, a lincosamide antibiotic, has been implicated in nephrotoxicity through oxidative stress-mediated mechanisms, leading to renal dysfunction. Activated charcoal, a widely used adsorbent, has shown potential in mitigating renal damage by adsorbing toxins and modulating oxidative stress. However, its efficacy in lincomycin-induced nephrotoxicity remains poorly understood. Aim: This study investigates the protective potential of activated charcoal against lincomycin-induced nephrotoxicity by assessing oxidative stress markers, renal function indices, and histopathological changes. Methodology: Twenty-five (25) Wistar rats were divided into five groups (n=5). Group I (Control) received normal saline, while Group II received lincomycin (200 mg/kg). Groups III, IV, and V were co-administered lincomycin with varying percentages of activated charcoal (25%, 50%, and 75%). Kidney function markers (creatinine, urea), oxidative stress indices (Superoxide Dismutase [SOD], Malondialdehyde [MDA]), and histopathological changes were evaluated. Results: Lincomycin administration significantly reduced creatinine (0.59±0.07 mg/dl) and urea (19.85±2.11 mg/dl) compared to controls (0.85±0.04 mg/dl, 25.78±1.19 mg/dl; P<0.05). Oxidative stress was evident in the lincomycin group, with a decrease in SOD (14.25±1.81 U/mg protein) and an increase in MDA. Activated charcoal co-administration mitigated these effects, improving kidney function and oxidative stress parameters. Conclusion: Activated charcoal offers protective effects against lincomycin-induced nephrotoxicity by reducing oxidative stress and preserving renal function. Its potential as an adjunct therapy in mitigating antibiotic-induced kidney damage warrants further investigation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.63593/jimr.2788-7022.2025.08.001
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
